Le Lézard
Classified in: Health
Subjects: MAV, CCA

WELL Health to Host Second Quarter 2019 Investor Conference Call


VANCOUVER, Aug. 19, 2019 /CNW/ - WELL Health Technologies Corp. ("WELL") (TSX.V: WELL), a company focused on consolidating and modernizing clinical and digital assets within the primary healthcare sector, will hold a call to discuss its 2019 second quarter financial results on Thursday August 22, 2019 at 1:00 pm ET (10:00 am PT). The call will be hosted by Hamed Shahbazi, Chairman and Chief Executive Officer; Eva Fong, Chief Financial Officer and Pardeep S. Sangha Vice President Corporate Strategy and Investor Relations.

Conference Call Details:
Date:  Thursday August 22, 2019
Time:  1:00 pm Eastern Time (10:00 am Pacific Time)
Dial-in:  1-416-764-8609 (Toronto local) or 1-888-390-0605 (Toll-Free)
Conference ID:  54030543

Replay accessible for 7 days:
Replay dial-in: 1-416-764-8677 or 1-888-390-0541
Playback passcode:  030543#

About WELL

WELL is a unique company that operates Primary Healthcare Facilities as well as a significant EMR or Electronic Medical Records business that supports the digitization of such clinics.  WELL's overarching objective is to empower doctors to provide the best and most advanced care possible leveraging the latest trends in digital health.  In the last 12 months, WELL physicians served approximately 600,000 patient visits through its network of 19 medical clinics.  WELL is publicly traded on the TSX Venture Exchange under the symbol WELL.V.  WELL was recognized as a TSX Venture 50 Company in 2018 and 2019.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE WELL Health Technologies Corp.


These press releases may also interest you

at 08:29
The American Red Cross depends on the power of volunteers and the generosity of donors to deliver its lifesaving mission. Helping the organization stay ready for emergencies throughout the year are some of the most generous corporate partners...

at 08:25
The "OPDIVO Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets. A detailed picture of...

at 08:25
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA...

at 08:20
4Sight Labs, pioneers in biometric monitoring solutions for custody environments, today announced the launch of OverWatchtm, the first-of-its-kind, comprehensive biometric monitoring system designed to address the wellness and safety of individuals...

at 08:20
Anixa Biosciences, Inc. ("Anixa" or the "Company") , a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board....

at 08:15
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended...



News published on and distributed by: